论文部分内容阅读
目的探讨复方丹参联合苦参素注射液治疗中度慢性乙型肝炎患者的临床疗效。方法选取2011年12月至2014年12月河南医学高等专科学校附属医院收治的中度慢性乙型肝炎患者140例为研究对象,按随机数字表法分为对照组和观察组,每组70例。对照组患者采用复方丹参注射液治疗,观察组患者采用复方丹参注射液与苦参素注射液联合治疗,比较两组患者治疗前后的血常规、乙型肝炎病毒标志物、肝功能、肝纤维化指标。结果治疗后观察组患者白细胞升高43例,血小板升高30例;对照组患者分别为30例和17例,两组差异有统计学意义(P<0.05);观察组患者HBV-DNA和HBe Ag转阴分别为27例和30例,对照组分别为7例和8例,两组差异有统计学意义(P<0.05);两组患者治疗前后肝功能变化差异均无统计学意义(均P>0.05);观察组患者肝纤维化指标改善情况优于对照组,差异有统计学意义(P<0.05)。结论复方丹参联合苦参素注射液对中度慢性乙型肝炎的临床治疗效果较好,明显优于常规保肝治疗,且用药安全。
Objective To investigate the clinical efficacy of compound Danshen injection combined with oxymatrine injection in patients with moderate chronic hepatitis B. Methods A total of 140 patients with moderate chronic hepatitis B who were admitted to the Affiliated Hospital of Henan Medical College from December 2011 to December 2014 were selected as study objects and divided into control group and observation group according to random number table method, . Patients in the control group were treated with compound Danshen injection. Patients in the observation group were treated with compound Danshen injection and oxymatrine injection. Blood samples, hepatitis B virus markers, liver function and liver fibrosis were compared between the two groups before and after treatment. index. Results In the observation group, there were 43 cases of leukocytosis and 30 cases of thrombocytopenia in the observation group; 30 cases in the control group and 17 cases in the observation group, the difference was statistically significant (P <0.05); HBV-DNA and HBe Ag was negative in 27 cases and 30 cases respectively, while the control group was 7 cases and 8 cases, respectively, with significant difference between the two groups (P <0.05). There was no significant difference in liver function between the two groups before and after treatment (both P> 0.05). The improvement of liver fibrosis indicators in observation group was better than that in control group, the difference was statistically significant (P <0.05). Conclusion Fufang Danshen combined with oxymatrine injection has a good effect on the treatment of moderate chronic hepatitis B, which is obviously better than the conventional hepatoprotective therapy and is safe for medication.